SPORE University of Texas M. D. Anderson Cancer Center-Leukemia

SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病

• 批准号: 10911713
• 负责人: Elizabeth J Shpall
• 金额: $ 91.86万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10911713
• 关键词: ATAC-seq; Achievement; Activated Natural Killer Cell; Acute Myelocytic Leukemia; Acute leukemia; Address; Administrator; Adoptive Transfer; Advocate; Aftercare; Allogenic; Antigens; Award; Azacitidine; B lymphoid malignancy; BCL1 Oncogene; BCL2 gene; Biological Markers; Blood; Blood Proteins; Bone Marrow; CAR T cell therapy; CASP9 gene; CD28 gene; CD70 antigen; Cancer Center; Cancer Center Support Grant; Caring; Cell Death; Cell Differentiation process; Cell Line; Cell Proliferation; Cell Shape; Cell Survival; Cell Therapy; Cell physiology; Cells; Cellular Stress; ChIP-seq; Chemoresistance; Chromatin; Clinic; Clinical; Clinical Protocols; Clinical Trials; Collaborations; Communication; Complement; Complex; Consultations; Cryopreservation; Cytarabine; Cytoplasm; DNA; Data; Databases; Dependence; Development; Disease; Disease remission; Doctor of Medicine; Dose; Doxorubicin; Drug Targeting; EZH2 gene; Electronic Mail; Eligibility Determination; Endogenous Retroviruses; Endowment; Engineering; Enrollment; Ensure; Event; Exhibits; Exposure to; FLT3 inhibitor; Future; Gene Silencing; Generations; Genes; Genetic Transcription; Genotype; Goals; Good Manufacturing Process; Grant; Hematologic Neoplasms; Hematopoietic stem cells; Hodgkin Disease; Human; IL3RA gene; In Vitro; In complete remission; Induction of Apoptosis; Infrastructure; Institution; Institutional Review Boards; Interferons; Interleukin-15; Laboratories; Leukemic Cell; Ligands; Liposomes; Lymphoid Cell; Maintenance; Marrow; Measures; Metabolic; Metabolism; Methods; Minority; Mitochondrial Electron Transport Complex I; Modality; Modeling; Monitor; Morphology; Multiple Myeloma; Mus; Mutation; National Cancer Institute; Natural Killer Cells; Nature; Neoadjuvant Therapy; Oncogenes; Organ; Outcome; Oxidative Phosphorylation; Pathogenesis; Pathologic; Pathology; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Phase I/II Clinical Trial; Phenotype; Phosphorylation Inhibition; Play; Policies; Population; Postremission Therapy; Preclinical Testing; Predisposition; Preparation; Prognosis; Progress Reports; Proliferating; Protein Array; Proteomics; Protocols documentation; Publications; Publishing; RNA; Refractory; Regulation; Relapse; Relaxation; Reporting; Reproduction spores; Research; Research Personnel; Research Project Grants; Residual Neoplasm; Residual state; Resistance; Retrotransposon; Risk; Safety; Sampling; Serum; Signal Transduction; Site; Specimen; Stem cell transplant; Strategic Planning; Stress; T-Lymphocyte; TNF gene; Testing; Texas; Therapeutic; Tissues; Toxic effect; Transcription Elongation; Transcription Initiation; Translational Research; Treatment Efficacy; Tumor Antigens; Tumor Burden; Umbilical Cord Blood; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Up-Regulation; Woman; Work; acute myeloid leukemia cell; adverse outcome; antileukemic activity; biobank; biological adaptation to stress; career; cell killing; cellular transduction; chemotherapeutic agent; chemotherapy; chimeric antigen receptor; cohort; cost; cytopenia; design; drug development; drug testing; ds-DNA; efficacy testing; engineered NK cell; experience; experimental study; first-in-human; genetically modified cells; graft vs host disease; improved; improved outcome; in vitro activity; in vitro testing; in vivo; inhibitor; inhibitor therapy; lectures; leukemia; leukemia relapse; leukemia treatment; leukemic stem cell; lymphoid neoplasm; manufacture; manufacturing process; meetings; member; mesenchymal stromal cell; metabolic fitness; mitochondrial fitness; mouse model; nanomolar; neoplastic cell; next generation; novel; novel therapeutics; older patient; overexpression; partial response; patient derived xenograft model; peripheral blood; pharmacodynamic biomarker; pharmacologic; point of care; prevent; progenitor; programs; prospective; protein expression; receptor; recruit; relapse patients; repository; response; screening; sensor; single cell analysis; small molecule; standard care; stem cells; success; suicide gene; symposium; synergism; targeted therapy trials; tool; transcriptome sequencing; transcriptomics; transplantation therapy; tumor; tumor heterogeneity; vector; weapons; web site

Project Abstract N/A

项目摘要 不适用

项目成果

Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.

TET2 靶基因的低甲基化确定了急性髓系白血病的可治愈亚群。

• DOI: 10.1093/jnci/djv323
• 发表时间: 2016-02-01
• 期刊: Journal of the National Cancer Institute
• 作者: J. Yamazaki;Rodolphe Taby;J. Jelinek;N. J. Raynal;M. Cesaroni;S. Pierce;S. Kornblau;C. Bueso;F. Rav;i;i;H. Kantarjian;J. Issa
• 通讯作者: J. Issa

FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.

FZR1 缺失会增加对 DNA 损伤的敏感性，从而促进小鼠和人类 B 细胞急性白血病。

• DOI: 10.1182/blood-2016-07-726216
• 发表时间: 2017-04-06
• 期刊: Blood
• 影响因子: 20.3
• 作者: J. Ishizawa;E. Sugihara;S. Kuninaka;K. Mogushi;K. Kojima;C. Benton;Ran Zhao;D. Chachad;Norisato Hashimoto;R. Jacamo;Y. Qiu;S. Yoo;S. Okamoto;M. Andreeff;S. Kornblau;H. Saya
• 通讯作者: H. Saya

A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.

一种针对白血病抗原 PR1/HLA-A2 的新型 T 细胞参与双特异性抗体。

• 发表时间: 2018
• 作者: Herrmann, Amanda C;Im, Jin S;Pareek, Sumedha;Ruiz;Lu, Sijie;Sergeeva, Anna;Mehrens, Jennifer;He, Hong;Alatrash, Gheath;Sukhumalchandra, Pariya;St John, Lisa;Clise;Zha, Dongxing;Molldrem, Jeffrey J
• 通讯作者: Molldrem, Jeffrey J

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.

预测基因特征决定肿瘤对 MDM2 抑制的敏感性。

• 发表时间: 2018-05-15
• 影响因子: 11.2
• 作者: Ishizawa, Jo;Nakamaru, Kenji;Seki, Takahiko;Tazaki, Koichi;Kojima, Kensuke;Chachad, Dhruv;Zhao, Ran;Heese, Lauren;Ma, Wencai;Ma, Man Chun John;DiNardo, Courtney;Pierce, Sherry;Patel, Keyur P;Tse, Archie;Davis, R Eric;Rao, Arvind;Andreeff
• 通讯作者: Andreeff

Mean residual life regression with functional principal component analysis on longitudinal data for dynamic prediction.

平均剩余寿命回归与纵向数据的功能主成分分析用于动态预测。

• 发表时间: 2018-12
• 影响因子: 1.9
• 作者: Lin, Xiao;Lu, Tao;Yan, Fangrong;Li, Ruosha;Huang, Xuelin
• 通讯作者: Huang, Xuelin